Research LettersAminopeptidase P in individuals with a history of angio-oedema on ACE inhibitors
References (5)
- et al.
Plasma bradykinin in angio-oedema
Lancet
(1998) - et al.
Drug-induced angioedema without urticaria
Drug Saf
(2001)
There are more references available in the full text version of this article.
Cited by (163)
The Importance of Complement Testing in Acquired Angioedema Related to Angiotensin-Converting Enzyme Inhibitors
2021, Journal of Allergy and Clinical Immunology: In PracticeACE inhibitor-mediated angioedema
2020, International ImmunopharmacologyBiological diagnosis of bradykinin mediated angioedema: CREAK recommendations
2019, Presse MedicaleCardiovascular and Diabetic Medications That Cause Bradykinin-Mediated Angioedema
2017, Journal of Allergy and Clinical Immunology: In PracticeCitation Excerpt :When ACE is inhibited, as in the use of ACEi, the other degrading enzymes play a larger role in the breakdown of bradykinin. Therefore, individuals who have decreased activity in one or more of these enzymes (ie, APP, dipeptidyl peptidase IV) have a higher risk for ACEi-induced angioedema.14 Genetic polymorphisms in these degradation enzymes may explain why Americans of African heritage are at increased risk for angioedema.15
The Angiotensin-Converting-Enzyme-Induced Angioedema
2017, Immunology and Allergy Clinics of North AmericaPGX: Pharmacogenomics During Generation X
2016, Advances in Chronic Kidney Disease
Copyright © 2002 Elsevier Ltd. All rights reserved.